Not independent
Tenure on this board
3.4 yrs
Meeting calendar
PALI · Annual meeting · Friday, October 17, 2025
Palisade Bio Inc
3 nominees · 3 ballot items.
Election of three directors; ratification of Baker Tilly US, LLP as independent registered public accounting firm for 2025; approval of a reverse stock split with ratios between 1-for-5 and 1-for-50.
Market cap
$342M
1Y TSR
+170.9%
Board grade
C-
Record date
Sep 12, 2025
Filing
DEF 14A
Meeting concluded · Oct 17, 2025
Follow how the vote landed and what changed on Palisade Bio Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORTo elect three directors to hold office until the 2026 Annual Meeting or until a successor is duly elected and qualified or until the director’s earlier death, resignation or removal.
- 2
Ratification of Audit Committee's Selection of Baker Tilly US, LLP as Our Independent Registered Public Accounting Firm for 2025
ManagementBoard: FORTo ratify Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
- 3
Approval of the Reverse Stock Split Proposal
ManagementBoard: FORTo approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split using a split ratio between, and including, 1-for-5 and 1-for-50 with the actual ratio within this range to be selected by the Board if and when effected following stockholder approval.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
5.2 yrs
Independent
Tenure on this board
1.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | B Group, Inc. | 6.6% | 11,414,285 | $20M |
| 2 | JANUS HENDERSON GROUP PLC | 6.2% | 10,689,452 | $19M |
| 3 | Octagon Capital Advisors LP | 5.9% | 10,276,317 | $18M |
| 4 | PERCEPTIVE ADVISORS LLC | 5.1% | 8,928,149 | $16M |
| 5 | AMERIPRISE FINANCIAL INC | 5.0% | 8,711,385 | $15M |
| 6 | Commodore Capital LP | 4.1% | 7,181,062 | $13M |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 4.1% | 7,124,116 | $12M |
| 8 | FRANKLIN RESOURCES INC | 3.3% | 5,785,189 | $10M |
| 9 | GOLDMAN SACHS GROUP INC | 3.1% | 5,373,951 | $9M |
| 10 | Eversept Partners, LP | 2.9% | 4,987,499 | $9M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Palisade Bio Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Seer IncSEER
Annual meeting·Jul 28, 2026·$91M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Palisade Bio Inc 2025 annual meeting?
- Palisade Bio Inc (PALI) holds its 2025 annual shareholder meeting on Friday, October 17, 2025.
- What is the record date for the Palisade Bio Inc 2025 meeting?
- The record date for the Palisade Bio Inc 2025 meeting is Friday, September 12, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Palisade Bio Inc's 2025 meeting?
- The board is presenting 3 director nominees at the Palisade Bio Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Palisade Bio Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Palisade Bio Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.